Evidence map›Paper›PMID 36411769›Full record

ArticleBioMed research international2022

Suppressive, Curative, and Prophylactic Effects of

Eyob Tekalign, Getnet Tadege, Nebeyi Fisseha, Dejen Nureye

Abstract read
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eyob TekalignDepartment of Medical Laboratory Sciences, College of Medicine and Health Sciences, Mizan-Tepi University, P.O. Box 260, Mizan-Aman, Ethiopia.ORCID https://orcid.org/0000-0002-3284-5951
Getnet TadegeDepartment of Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Aman, Ethiopia.ORCID https://orcid.org/0000-0002-2582-5872
Nebeyi FissehaDepartment of Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Aman, Ethiopia.ORCID https://orcid.org/0000-0002-8296-3104
Dejen NureyeDepartment of Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Aman, Ethiopia.ORCID https://orcid.org/0000-0001-9919-8376

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The artemisinin partial resistance is believed to be spread to artemisinin-based combination therapy partner drugs. As a result, new antiplasmodial compounds are required to treat resistant malaria infections. In the invention of antimalarial substances, claimed medical plants are precious resources. So, the current study was designed to assess the antiplasmodial effects of

Indexed as

AntimalarialsArtemisininsMaesaMalariaParasitesAnimalsChloroformMethanolMicePlasmodium bergheiRodentiaAntimalarialsArtemisininsChloroformMethanol

Identifiers

PMID36411769
PMCPMC9675603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.